StockData
Quoin Pharmaceuticals Ltd. logo

Quoin Pharmaceuticals Ltd. (QNRX) company profile

QNRXNasdaqPharmaceutical Preparations
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.36−0.20 (-5.62%)

Close on Nov 17, 2026Market cap $6.75MP/E –Yield –

About Quoin Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical business focused on developing and commercializing therapeutic solutions for rare and orphan diseases. The company concentrates on conditions that currently lack approved therapies or have very restricted treatment options. Its lead investigational asset, QRX003, is a topical lotion formulated to address rare genetic skin disorders, primarily Netherton Syndrome as well as Peeling Skin Syndrome. Quoin is also developing additional pipeline candidates, including QRX008 for scleroderma and QRX009, which utilizes topical rapamycin formulations for multiple rare conditions. Its target patient populations consist of individuals diagnosed with these rare medical disorders.

The company operates across multiple international jurisdictions through clinical studies and partnerships. Its clinical trial footprint includes six sites in the United States, along with clinical sites and studies across the United Kingdom, Spain, France, Ireland, Austria, the Netherlands, and New Zealand. Additionally, Quoin maintains commercial distribution partnerships covering sixty-one countries outside its core commercial focus areas of the United States, Western Europe, and Japan. The provided text does not state the location of the company's headquarters.

Summary of the business section of Quoin Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Quoin Pharmaceuticals Ltd.
Founded
1986
Headquarters
Ashburn, VA
Address
42127 Pleasant Forest Court 20148-7349
Phone
(703) 980-4182
Employees
4, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Auditor
Marcum LLP, Morristown, New Jersey

Stock & identifiers

Ticker
QNRX
Former tickers
APOP until Apr 14, 2022
Exchange
Nasdaq
IPO date
Aug 1, 2016
Shares outstanding
70M, Aug 12, 2026
Public float
$5.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-35 reverse, Apr 9, 2025; 1-for-12 reverse, Jul 18, 2023; 1-for-4 reverse, Sep 24, 2021; 1-for-5 reverse, Oct 23, 2019
SEC CIK
1671502
CUSIP
74907L409
ISIN
US74907L4095
FIGI
BBG00D9PB2L6
Share class FIGI
BBG00D9PB389
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael MyersChief Executive Officer, Director37,713
Denise P. CarterChief Operating Officer, Director37,709
Sally Bridget LawlorChief Financial Officer10,684
Gordon DunnChief Financial Officer151,077
Dennis LangerDirector49,687
Anthony James CulverwellDirector40,364
Michael T. SemberDirector–
Joseph Patrick CooperDirector–
Natalie Ee Mun LeongDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.51M$1.60M$858.29K$2–
FY2024$1.41M$1.03M$933.95K$4–
FY2023$1.26M$1.22M$923.45K$29–
FY2022$1.97M$941.20K$1.63M$6–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 1, 2016
Offer price
$6.50
Securities offered
1,292,308
Gross proceeds
$8.40M
Exchange
Nasdaq
First trading day
Aug 1, 2016
Lock-up ends (est.)
Jan 28, 2017

“Per ADS and Warrant Total Initial public offering price $ 6.50 $ 8,400,002 Underwriting discounts and commissions (1) $ 0.455 $ 588,000 Proceeds, before expenses, to us (2) $ 6.045 $ 7,812,002 (1) In addition, we have agreed to reimburse the representative of the underwriters for certain expenses and to issue to the represen”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had four full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 20, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 31, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 3, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 15, 2021Name changeName changed from Cellect Biotechnology Ltd. to Quoin Pharmaceuticals, Ltd.
Aug 3, 2021DelistingNotice of delisting from exchange (Form 25)
Jun 16, 2021MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 1, 2016IPOInitial public offering priced (424B4 prospectus)
Jul 27, 2016ListingRegistration of securities on an exchange (Form 8-A)
Jul 7, 2016Name changeName changed from Cellect Biomed Ltd. to Cellect Biotechnology Ltd.

See a number that looks wrong?